

NUCLEAR DATA PRIORITIES FOR NON-ENERGY APPLICATIONS

Int. Atomic Energy Agency




Vienna, Austria



**Roberto Capote, Deputy Section Head
NAPC-Nuclear Data Section, IAEA**

Nuclear Sciences and Applications: Serving Basic Human Needs



Atoms for Health: Disease Prevention and Control



- ✓ Nutrition
- ✓ Nuclear Medicine
- ✓ Radiobiology and Radiotherapy
- ✓ Dosimetry and Medical Physics
- ✓ Fighting Global Cancer



NON-ENERGY APPLICATIONS

Non-energy ? Anything? A fuzzy definition...

- Medical applications: radionuclide production
- Astrophysics
- Planetary defence
- Space exploration
- Space safety
- Geological applications
- ...



ND needs in space propulsion

Nuclear thermal propulsion technologies are being developed for in-space propulsion



Viewing Kelsa Palomares's sc...



Nuclear thermal propulsion is an in-space propulsion technology being evaluated for crewed Mars Missions

▪ **Major components:**

- **Moderators:** metallic hydrides (ZrH_x , YH_x), beryllium compounds (Be, BeO, Be_2C) or combinations there-of
- **Control:** Be, B_4C
- **Fuel forms:** refractory U-ceramics (UO_2 , UC_2 , UC, UN, UC-ZrC), coated fuel particles
- **Structural materials:** Refractory ceramics (carbides, graphite), refractory metals (W, Mo)

▪ **Unique design features:**


- Reactor design requires unique materials to enable operation at extremely high temperature
- Wide temperature range needed for cross sections to inform the reactor design
 - ❖ Coldest regions of the reactor are cooled by liquid hydrogen
 - ❖ Hottest regions operate as a heat exchanger above 2700 K
- High Assay Low Enriched Uranium (HALEU)
 - ❖ Synergies with ongoing advanced, small, or microreactors?
- Use environment: in-space background radiation and impacts to overall system design
- Nuclear data needed for both reactor and shielding design
 - ❖ Reactor design requires accurate prediction of reactivity over a range of operational modes
 - ❖ Shielding design must ensure that critical components, systems and crew are not exposed to neutron and gamma sources above design limits




LA-UR-11-05198



Fuel Element



Reactor



Engine

NASA

Taken from WANDA 2021 presentation by K. Palomares




ND needs for planetary defense

Nuclear data is the Viewing Lansing Horan's appl... on of this work.



- For a given problem geometry and material composition, **nuclear cross sections are how bulk neutron interactions are mapped to energy deposition profiles.**



changing the neutron energy changes:

1. cross section magnitude
2. mean-free-path
3. spatial extent/distribution
4. energy deposition profiles

changing the neutron energy changes:

1. open/closed reaction channels
2. endothermic/exothermic reactions
3. energy coupling efficiencies

Nuclear data ultimately determines the end results of asteroid deflection.

8

Taken from WANDA 2021 presentation by Lansing Horan



NUCLEAR DATA FOR MEDICAL APPLICATIONS

- ❑ The utilization of radiation in medicine for diagnosis and treatment dates from the 19th century, almost from the time x-rays (atomic data) and radioactivity (nuclear data) were discovered
- ❑ Now its use is deeply embedded in medical practice. For many purposes, it is indispensable – both for diagnosis and for treatment





IAEA
International Atomic Energy Agency

INDC(NDS)-0776
Distr. G+NM+SD

INDC International Nuclear Data Committee

Summary Report

Technical Meeting on

Nuclear Data for Medical Applications

IAEA Headquarters
Vienna, Austria
10-13 December 2018

Prepared by

Jonathan W. Engle
Department of Medical Physics
WIMR Cyclotron Laboratory
University of Wisconsin
Madison WI 53711
USA

Alan L. Nichols
Department of Physics
University of Surrey
Guildford, UK

and

Roberto Capote Noy
IAEA Nuclear Data Section
Vienna, Austria

May 2019

IAEA Nuclear Data Section

NUCLEAR DATA NEEDS FOR MEDICAL APPLICATIONS

IAEA meeting in 2018



THREE DISTINCT MEDICAL FIELDS

- Diagnostic radiology
 - 100% diagnostic
- Radiotherapy
 - 100% treatment
- Nuclear medicine
 - 80% diagnostic
 - 10% treatment



Multidisciplinary team: physicians, physicists, radiographers,...

Radionuclide	Clinical use	Application	Decay mode (used emission)	$T_{\frac{1}{2}}$
^{99m}Tc	~80%	Imaging	IT (γ 140keV)	6.0h
^{133}Xe	~1%	Imaging	β^- (γ 81keV)	5.3d
^{111}In	~1%	Imaging	EC (γ 171, 245keV)	2.8d
^{123}I	~0.5%	Imaging	EC (γ 159keV)	13h
^{201}Tl	~0.1% (\downarrow)	Imaging	EC (γ 135, 167keV)	3.0d
^{51}Cr	~5%	Blood tests	EC (γ 320keV)	28d
^{18}F	~2% (\uparrow)	PET imaging	β^+ (γ 511keV)	110min
^{11}C	~0.6%	PET imaging	β^+ (γ 511keV)	20min
^{15}O	~0.3%	PET imaging	β^+ (γ 511keV)	2.1min
^{124}I	Research	PET imaging	β^+ (γ 511keV)	4.2d
^{131}I	~5%	Therapy	β^- (806keV; γ 364keV)	8.1d
^{32}P	~0.2%	Therapy	β^- (1706keV)	14d
^{153}Sm	~0.2%	Therapy	β^- (810keV; γ 103keV)	47h
^{89}Sr	~0.1%	Therapy	β^- (1480keV)	51d
^{177}Lu	Research	Therapy	β^- (497keV; γ 208keV)	6.6d
^{211}At	Research	Therapy	α (5870, 7450keV)	7.2h



NUCLEAR DATA FOR RADIOISOTOPE PRODUCTION



IAEA projects on radioisotopes: Overview

Radioisotopes for medical applications:
accelerator and reactor production

I. CRP on “Charged Particle Cross-Section Database for Medical Radioisotope Production: Diagnostic Radioisotopes and Monitor Reactions”-completed in 2002 (updated in 2007)

IAEA-TECDOC-1211

II. CRP on “Nuclear Data for the Production of Therapeutic Radionuclides” 2003-2007


IAEA TRS 473 (2011)

CRP on “CP monitor reactions and nuclear data for non-standard positron emitters”, 2012-2017




Diagnostic radioisotope production

<https://nds.iaea.org/medportal/>



Radioisotope production data

<https://nds.iaea.org/relnsd/isotopia/isotopia.html>

 **Medical Isotope Browser**
IAEA Nuclear Data Section

Examples 1 Incident - Exit energies
2 Incident energy - Thickness, and user σ
3 Energy scan 4 Composite target

Previous run:

Product ?
 all products

Projectile ?
 p D α T ^3He

Target ? **composition**

Density [g/cm^3] ?
blank = default

Thickness [mm] [mg/cm^2] ?

Exit energy [MeV] ?

Incident energy [MeV] ?




Incident energy scan ?
 $\leq E \leq$ $\Delta E:$







Current [μA]





Irradiation T ?
 d 0 h m

Post EOB T ?
 d 0 h m

Cross section
IAEA + TENDL **custom**

Data    **Guide** 

Medical Isotope Browser

pick one example to start

- 1 Incident - Exit energies
- 2 Energy scan
- 3 Composite target
- 4 Incident energy - Thickness, and user σ



Beam monitor reactions (reference XS)

Monitor Reactions 2017

A. Hermanne et al., Nucl. Data Sheets 148 (2018) 338-382

Protons

$^{27}\text{Al}(p,x)^{22}\text{Na}$
 $^{27}\text{Al}(p,x)^{24}\text{Na}$
 $^{\text{nat}}\text{Ti}(p,x)^{48}\text{V}$
 $^{\text{nat}}\text{Ti}(p,x)^{46}\text{Sc}$
 $^{\text{nat}}\text{Ni}(p,x)^{57}\text{Ni}$
 $^{\text{nat}}\text{Cu}(p,x)^{62}\text{Zn}$
 $^{\text{nat}}\text{Cu}(p,x)^{63}\text{Zn}$
 $^{\text{nat}}\text{Cu}(p,x)^{65}\text{Zn}$
 $^{\text{nat}}\text{Cu}(p,x)^{56}\text{Co}$
 $^{\text{nat}}\text{Cu}(p,x)^{58}\text{Co}$
 $^{\text{nat}}\text{Mo}(p,x)^{96\text{m}+g}\text{Tc}$

Deuterons

$^{27}\text{Al}(d,x)^{22}\text{Na}$
 $^{27}\text{Al}(d,x)^{24}\text{Na}$
 $^{\text{nat}}\text{Ti}(d,x)^{48}\text{V}$
 $^{\text{nat}}\text{Ti}(d,x)^{46}\text{Sc}$
 $^{\text{nat}}\text{Fe}(d,x)^{56}\text{Co}$
 $^{\text{nat}}\text{Ni}(d,x)^{61}\text{Cu}$
 $^{\text{nat}}\text{Ni}(d,x)^{56}\text{Co}$
 $^{\text{nat}}\text{Ni}(d,x)^{58}\text{Co}$
 $^{\text{nat}}\text{Cu}(d,x)^{62}\text{Zn}$
 $^{\text{nat}}\text{Cu}(d,x)^{63}\text{Zn}$
 $^{\text{nat}}\text{Cu}(d,x)^{65}\text{Zn}$

^3He -particles

$^{27}\text{Al}(^3\text{He},x)^{22}\text{Na}$
 $^{27}\text{Al}(^3\text{He},x)^{24}\text{Na}$
 $^{\text{nat}}\text{Ti}(^3\text{He},x)^{48}\text{V}$
 $^{\text{nat}}\text{Cu}(^3\text{He},x)^{66}\text{Ga}$
 $^{\text{nat}}\text{Cu}(^3\text{He},x)^{63}\text{Zn}$
 $^{\text{nat}}\text{Cu}(^3\text{He},x)^{65}\text{Zn}$

Alpha-particles

$^{27}\text{Al}(\alpha,x)^{22}\text{Na}$
 $^{27}\text{Al}(\alpha,x)^{24}\text{Na}$
 $^{\text{nat}}\text{Ti}(\alpha,x)^{51}\text{Cr}$
 $^{\text{nat}}\text{Cu}(\alpha,x)^{66}\text{Ga}$
 $^{\text{nat}}\text{Cu}(\alpha,x)^{67}\text{Ga}$
 $^{\text{nat}}\text{Cu}(\alpha,x)^{65}\text{Zn}$

Main

Monitor Reactions 2007

Gamma Emitters

Positron Emitters

Therapeutic Isotopes

Last edited by: S. Takacs: Aug. 2019.



Gamma Emitters

K. Gul et al., IAEA TECDOC 1211, Vienna, 2001

F. T. Tarkanyi et al., J. Radioanal. Nucl. Chem. 319 (2018) 487-531

51Cr

$^{51}\text{V}(\text{p},\text{n})^{51}\text{Cr}$
 $^{51}\text{V}(\text{d},2\text{n})^{51}\text{Cr}$
 $^{55}\text{Mn}(\text{p},\text{x})^{51}\text{Cr}$
 $^{55}\text{Mn}(\text{d},\text{x})^{51}\text{Cr}$
 $^{\text{nat}}\text{Fe}(\text{p},\text{x})^{51}\text{Cr}$
 $^{\text{nat}}\text{Ti}(\alpha,\text{x})^{51}\text{Cr}$

99mTc

$^{100}\text{Mo}(\text{p},\text{x})^{99}\text{Mo}$
 $^{100}\text{Mo}(\text{d},\text{x})^{99}\text{Mo}$
 $^{100}\text{Mo}(\text{p},2\text{n})^{99\text{m}}\text{Tc}$
 $^{100}\text{Mo}(\text{d},3\text{n})^{99\text{m}}\text{Tc}$
 $^{100}\text{Mo}(\gamma,\text{n})^{99}\text{Mo}$
 $^{98}\text{Mo}(\text{n},\gamma)^{99}\text{Mo}$
 $^{100}\text{Mo}(\text{n},2\text{n})^{99}\text{Mo}$
 $^{238}\text{U}(\gamma,\text{f})^{99}\text{Mo}$

123I

$^{123}\text{Te}(\text{p},\text{n})^{123}\text{I}$
 $^{124}\text{Te}(\text{p},2\text{n})^{123}\text{I}$
 $^{124}\text{Te}(\text{p},\text{n})^{124}\text{I}$
 $^{127}\text{I}(\text{p},5\text{n})^{123}\text{Xe}$
 $^{127}\text{I}(\text{p},3\text{n})^{125}\text{Xe}$
 $^{124}\text{Xe}(\text{p},2\text{n})^{123}\text{Cs}$
 $^{124}\text{Xe}(\text{p},\text{pn})^{123}\text{Xe}$
 $^{124}\text{Xe}(\text{p},\text{x})^{123}\text{Xe}$
 $^{124}\text{Xe}(\text{p},\text{x})^{121}\text{I}$

201Pb

$^{203}\text{Tl}(\text{p},3\text{n})^{201}\text{Pb}$
 $^{203}\text{Tl}(\text{p},4\text{n})^{200}\text{Pb}$
 $^{203}\text{Tl}(\text{p},2\text{n})^{202\text{m}}\text{Pb}$

67Ga

$^{67}\text{Zn}(\text{p},\text{n})^{67}\text{Ga}$
 $^{68}\text{Zn}(\text{p},2\text{n})^{67}\text{Ga}$

81Rb

$^{82}\text{Kr}(\text{p},2\text{n})^{81}\text{Rb}$
 $^{\text{nat}}\text{Kr}(\text{p},\text{x})^{81}\text{Rb}$

111In

$^{111}\text{Cd}(\text{p},\text{n})^{111}\text{In}$
 $^{112}\text{Cd}(\text{p},2\text{n})^{111}\text{In}$

178W

$^{181}\text{Ta}(\text{p},4\text{n})^{178}\text{W}$
 $^{181}\text{Ta}(\text{p},4\text{n})^{178}\text{W}$
 $^{181}\text{Ta}(\text{p},4\text{n})^{178}\text{W}$

Main

Monitor Reactions 2017

Monitor Reactions 2007

Positron Emitters


Therapeutic Isotopes

Last edited by: S. Takacs: Aug. 2019.



Mo-99 production via (n,2n) reaction (deployed in Japan)

Selected experimental data for $^{100}\text{Mo}(n,2n)^{99}\text{Mo}$ reaction



Updated: Aug. 2018.



Positron Emitters


K. Gul et al., IAEA TECDOC 1211, Vienna, 2001
 F.T. Tarkanyi et al., J. Radioanalytical and Nucl. Chem. (2019) 319. 533-666

11C	52Mn	68Ga	82Rb	118Sb
$^{14}\text{N}(p,\alpha)^{11}\text{C}$	$^{52}\text{Cr}(p,n)^{52}\text{Mn}$	$^{68}\text{Zn}(p,n)^{68}\text{Ga}$	$^{\text{nat}}\text{Rb}(p,x)^{82}\text{Sr}$	$^{115}\text{Sn}(\alpha,n)^{118}\text{Te}$
13N	$^{52}\text{Cr}(d,2n)^{52}\text{Mn}$	$^{65}\text{Cu}(\alpha,n)^{68}\text{Ga}$	$^{85}\text{Rb}(p,4n)^{82}\text{Sr}$	$^{116}\text{Sn}(\alpha,2n)^{118}\text{Te}$
$^{16}\text{O}(p,\alpha)^{13}\text{N}$	55Co	$^{\text{nat}}\text{Ga}(p,x)^{68}\text{Ge}$	86Y	$^{\text{nat}}\text{Sb}(p,x)^{118}\text{Te}$
15O	$^{58}\text{Ni}(p,\alpha)^{55}\text{Co}$	$^{69}\text{Ga}(p,2n)^{68}\text{Ge}$	$^{86}\text{Sr}(p,n)^{86}\text{Y}$	$^{\text{nat}}\text{Sb}(d,x)^{118}\text{Te}$
$^{15}\text{N}(p,n)^{15}\text{O}$	$^{54}\text{Fe}(d,n)^{55}\text{Co}$	72As	$^{88}\text{Sr}(p,3n)^{86}\text{Y}$	120I
$^{14}\text{N}(d,n)^{15}\text{O}$	$^{56}\text{Fe}(p,2n)^{55}\text{Co}$	$^{75}\text{As}(p,4n)^{72}\text{Se}$	$^{85}\text{Rb}(\alpha,3n)^{86}\text{Y}$	$^{120}\text{Te}(p,n)^{120}\text{I}$
18F	61Cu	$^{\text{nat}}\text{Br}(p,x)^{72}\text{Se}$	89Zr	$^{122}\text{Te}(p,3n)^{120}\text{I}$
$^{18}\text{O}(p,n)^{18}\text{F}$	$^{61}\text{Ni}(p,n)^{61}\text{Cu}$	$^{\text{nat}}\text{Ge}(p,x)^{72}\text{As}$	$^{89}\text{Y}(p,n)^{89}\text{Zr}$	122I
$^{\text{nat}}\text{Ne}(d,x)^{18}\text{F}$	$^{60}\text{Ni}(d,n)^{61}\text{Cu}$	$^{\text{nat}}\text{Ge}(d,x)^{72}\text{As}$	$^{89}\text{Y}(d,2n)^{89}\text{Zr}$	$^{124}\text{Xe}(p,x)^{122}\text{Xe}$
44Sc	$^{64}\text{Zn}(p,\alpha)^{61}\text{Cu}$	73Se	90Nb	$^{127}\text{I}(p,6n)^{122}\text{Xe}$
$^{44}\text{Ca}(p,n)^{44}\text{Sc}$	62Cu	$^{75}\text{As}(p,3n)^{73}\text{Se}$	$^{93}\text{Nb}(p,x)^{90}\text{Nb}$	$^{127}\text{I}(d,7n)^{122}\text{Xe}$
$^{44}\text{Ca}(d,2n)^{44}\text{Sc}$	$^{63}\text{Cu}(p,2n)^{62}\text{Zn}$	$^{72}\text{Ge}(\alpha,3n)^{73}\text{Se}$	$^{89}\text{Y}(\alpha,3n)^{90}\text{Nb}$	128Cs
$^{43}\text{Ca}(d,n)^{44}\text{Sc}$	$^{63}\text{Cu}(d,3n)^{62}\text{Zn}$	76Br	94mTc	$^{133}\text{Cs}(p,6n)^{128}\text{Ba}$
$^{45}\text{Sc}(p,2n)^{44}\text{Ti}$	$^{\text{nat}}\text{Ni}(\alpha,x)^{62}\text{Zn}$	$^{76}\text{Se}(p,n)^{76}\text{Br}$	$^{92}\text{Mo}(\alpha,x)^{94\text{m}}\text{Tc}$	140Pr
$^{45}\text{Sc}(d,3n)^{44}\text{Ti}$	$^{62}\text{Ni}(p,n)^{62}\text{Cu}$	$^{77}\text{Se}(p,2n)^{76}\text{Br}$	$^{94}\text{Mo}(p,n)^{94\text{m}}\text{Tc}$	$^{141}\text{Pr}(p,2n)^{140}\text{Nd}$
52mMn	$^{62}\text{Ni}(d,2n)^{62}\text{Cu}$	$^{75}\text{As}(\alpha,3n)^{76}\text{Br}$	110mIn	$^{141}\text{Pr}(d,3n)^{140}\text{Nd}$
$^{\text{nat}}\text{Ni}(p,x)^{52}\text{Fe}$	66Ga	82mRb	$^{\text{nat}}\text{In}(p,x)^{110}\text{Sn}$	$^{\text{nat}}\text{Ce}(^3\text{He},x)^{140}\text{Nd}$
$^{55}\text{Mn}(p,4n)^{52}\text{Fe}$	$^{66}\text{Zn}(p,n)^{66}\text{Ga}$	$^{82}\text{Kr}(p,n)^{82\text{m}}\text{Rb}$	$^{108}\text{Cd}(\alpha,2n)^{110}\text{Sn}$	
$^{50}\text{Cr}(\alpha,2n)^{52}\text{Fe}$	$^{63}\text{Cu}(\alpha,n)^{66}\text{Ga}$	$^{82}\text{Kr}(d,2n)^{82\text{m}}\text{Rb}$	$^{110}\text{Cd}(p,n)^{110\text{m}}\text{In}$	
$^{52}\text{Cr}(p,n)^{52\text{m}}\text{Mn}$			$^{110}\text{Cd}(d,2n)^{110\text{m}}\text{In}$	
$^{52}\text{Cr}(d,2n)^{52\text{m}}\text{Mn}$			$^{107}\text{Ag}(\alpha,n)^{110\text{m}}\text{In}$	



F-18 production in small cyclotrons

Selected experimental data for $^{18}\text{O}(p,n)^{18}\text{F}$ reaction



Therapeutic Radionuclides

E. Betak et al., IAEA Technical Reports Series no. 473, Vienna, 2011

J.W. Engle et al., Nuclear Data Sheets 155 (2019) 56-74

64Cu

$^{64}\text{Ni}(p,n)^{64}\text{Cu}$

$^{64}\text{Ni}(d,2n)^{64}\text{Cu}$

$^{68}\text{Zn}(p,x)^{64}\text{Cu}$

$^{\text{nat}}\text{Zn}(d,x)^{64}\text{Cu}$

67Cu

$^{68}\text{Zn}(p,2p)^{67}\text{Cu}$

$^{70}\text{Zn}(p,x)^{67}\text{Cu}$

67Ga

$^{67}\text{Zn}(p,n)^{67}\text{Ga}$

$^{68}\text{Zn}(p,2n)^{67}\text{Ga}$

86Y

$^{86}\text{Sr}(p,n)^{86}\text{Y}$

103Pd

$^{103}\text{Rh}(p,n)^{103}\text{Pd}$

$^{103}\text{Rh}(p,x)^{102}\text{Rh}$

$^{103}\text{Rh}(d,2n)^{103}\text{Pd}$

$^{103}\text{Rh}(d,x)^{102}\text{Rh}$

111In

$^{111}\text{Cd}(p,n)^{111}\text{In}$

$^{112}\text{Cd}(p,2n)^{111}\text{In}$

114mIn

$^{114}\text{Cd}(p,n)^{114\text{m}}\text{In}$

$^{114}\text{Cd}(d,2n)^{114\text{m}}\text{In}$

$^{116}\text{Cd}(p,3n)^{114\text{m}}\text{In}$

124I

$^{124}\text{Te}(p,n)^{124}\text{I}$

$^{125}\text{Te}(p,2n)^{124}\text{I}$

$^{124}\text{Te}(d,2n)^{124}\text{I}$

125I

$^{125}\text{Te}(p,n)^{125}\text{I}$

$^{124}\text{Te}(d,n)^{125}\text{I}$

169Yb

$^{169}\text{Tm}(p,n)^{169}\text{Yb}$

$^{169}\text{Tm}(d,2n)^{169}\text{Yb}$

177Lu

$^{176}\text{Yb}(d,n)^{177\text{g}}\text{Lu}$

$^{176}\text{Yb}(d,p)^{177}\text{Yb}$

$^{176}\text{Yb}(d,x)^{177\text{g}}\text{Lu}$

186Re

$^{186}\text{W}(p,n)^{186}\text{Re}$

$^{186}\text{W}(d,2n)^{186}\text{Re}$

192Ir

$^{192}\text{Os}(p,n)^{192}\text{Ir}$

$^{192}\text{Os}(d,2n)^{192}\text{Ir}$

211At

$^{209}\text{Bi}(\alpha,2n)^{211}\text{At}$

$^{209}\text{Bi}(\alpha,3n)^{210}\text{At}$

131Cs

$^{131}\text{Xe}(p,n)^{131}\text{Cs}$

$^{133}\text{Cs}(p,3n)^{131}\text{Ba}$

225Ac

$^{232}\text{Th}(p,x)^{225}\text{Ac}$

$^{226}\text{Ra}(p,2n)^{225}\text{Ac}$

$^{232}\text{Th}(p,x)^{225}\text{Ra}$

227Th

$^{232}\text{Th}(p,x)^{227}\text{Th}$

$^{232}\text{Th}(p,x)^{227}\text{Ac}$

230U

$^{231}\text{Pa}(p,2n)^{230}\text{U}$

$^{231}\text{Pa}(d,3n)^{230}\text{U}$

$^{232}\text{Th}(p,3n)^{230}\text{Pa}$

Main

Monitor Reactions 2017

Monitor Reactions 2007

Gamma Emitters

Positron Emitters

Last edited by: S. Takacs: Aug. 2019.



- (n,γ)** Neutron data for production in a nuclear reactor
- (n,f)** – production of neutron excess radionuclides
- (n,p)** – experimental data and comparison with theory
- (p,xn)** Charged-particle data for production at a cyclotron
- (d,xn)** – production of neutron deficient radionuclides
- (α,xn)** – crucial role of nuclear data to check impurities
- (³He,xn)** – experimental data and comparison with theory

ESTABLISHED: ⁸⁹Sr, ⁹⁰Y, ¹³¹I, ¹⁵³Sm, ¹⁸⁶Re, ¹⁸⁸Re
³²P, ¹²⁵I, ¹⁰³Pd, ¹³⁷Cs, ¹⁹²Ir (brachytherapy)

EMERGING: ⁶⁴Cu, ⁶⁷Cu, ⁶⁷Ga, ⁸⁶Y, ¹⁰⁵Rh, ¹¹¹In, ^{114m}In,
¹²⁴I, ¹⁴⁹Pm, ¹⁶⁶Ho, ¹⁶⁹Y, ¹⁷⁷Lu
²¹¹At, ²¹³Bi, ²²⁵Ac (α emitters)

Nuclear Data for the Production of Therapeutic Radionuclides



REACTORS

Neutron-induced reactions

(n,γ)


(n,p)

(n,f)



$^{130}\text{Te}(n,\gamma)^{131}\text{Te} \rightarrow ^{131}\text{I}$ reaction


^{131}I production




ENSDF data




$^{130}\text{Te}(n,\gamma)^{131}\text{Te} \rightarrow ^{131}\text{I}$ reaction




$^{130}\text{Te}(n,\gamma)^{131}\text{Te} \rightarrow ^{131}\text{I}$ reaction



$^{64}\text{Zn}(n,p)^{64}\text{Cu}$ (raw EXFOR data)



$Zn(n,p)^{64}Cu$ reaction (evaluation)



$^{64}\text{Zn}(n,p)^{64}\text{Cu}$ reaction

Integral Validation

Neutron fields	Average cross section, mb		C/E
	Calculated [A]	Measured [*]	
^{235}U thermal fission neutron spectrum	38.9 ± 0.7 (1.7%)	38.9 ± 2.8	1.000
^{252}Cf spontaneous fission neutron spectrum	42.7 ± 0.80 (1.9%)	42.3 ± 0.9	1.009

[A] – Zolotarev, INDC(NDS)-0526, Vienna, Austria

[*] – evaluated experimental cross section



summary on RN production


- ❑ Experimental **data compilations** and **data selection**, **theoretical calculations** and the **final evaluations** for each of the reactions producing therapeutic radionuclides, have been undertaken
- ❑ Data will help to define **strategies for the production of radioisotopes** both at cyclotrons and reactors
- ❑ The resulting **completeness** and **accuracy** of the **cross-section data** for the production of these nuclides, along with a re-definition of their **decay data**, should be extremely beneficial in ensuring their **safe and efficient application** both in nuclear medicine and cancer therapy.




HEAVY CHARGED PARTICLE INTERACTIONS FOR RADIOTHERAPY





In 1946 Harvard physicist Robert Wilson (1914-2000) suggested that protons can be used clinically



Robert Wilson




Protons vs Photons




Special case: Paediatric patients

Photons




Protons



Photon integral dose is higher by a factor of 2-3 !

Bragg peaks vs exp. : ^{20}Ne @ 670 MeV/n

Dose vs depth distribution for 670 MeV/n ^{20}Ne ions on a water phantom. The green line is the FLUKA prediction. The symbols are exp data from LBL and GSI.



Taken from A. Ferrari presentation in 2010



PROBLEMS IN EVALUATED GAMMA SPECTRA

Nuclear data needs of gamma spectra (D. Lawrence & P. Peplowski)


- Carbon sequestration ()
- Active neutron interrogation (C. Romano et al)
- Non-proliferation applications (D. Matters)
- Planetary science (T. Prettyman et al)
- Subsurface exploration (M.-L. Mauborgne et al)
- Shielding and criticality safety (Miller et al.)

see WANDA 2021 presentations at:

<https://conferences.lbl.gov/event/504/>



ND needs in planetary gamma spectroscopy



Taken from WANDA 2021 presentation by D. Lawrence and P. Peplowski



ND needs in planetary gamma spectroscopy

Elements of Interest

- The needs of the planetary nuclear spectroscopy community are:
 - (n,n' γ) and (n, γ) gamma-ray production cross sections,
 - on natural targets of major and minor elements,
 - for each gamma-ray emission of interest,
 - over a wide range of neutron energies.
- This information needs to be accurately provided for use in radiation transport codes (Geant4, MCNP6) via appropriate libraries.
 - To date, no one library works for all gamma-ray lines.
 - New does not mean better – benchmarks show that ENDF VI is better than ENDF VIII!
- The list to the right shows the required element measurements for the three APL-led gamma-ray spectroscopy investigations currently in development.
 - It is complete in terms of elements, but it is not exhaustive in terms of gamma rays.
 - It also doesn't cover the needs of prior missions.
 - The list is not meant to imply that we do or don't have the data we need for these elements.

	Typical Gamma Rays (non-inclusive list)	Psyche GRS (Asteroid 16 Psyche)	MEGANE (Mars' Moon Phobos)	DraGNS (Saturn's Moon Titan)
H	(n, γ): 2223 keV		Y	Y
C	(n,n' γ): 4438 keV			Y
N	(n,n' γ): 2312 keV			Y
O	(n,n' γ): 6129 keV (n,n' $\alpha\gamma$): 4438 keV		Y	Y
Na	(n,n' γ): 440 keV		Y	Y
Mg	(n,n' γ): 1369 keV		Y	Y
Al	(n,n' γ): 843, 1014, 2211 keV	Y		
Si	(n,n' γ): 1778 keV (n, γ): 3539, 4934 keV	Y	Y	
P	(n,n' γ): 2233 keV			Y
S	(n,n' γ): 2232 keV	Y		Y
Cl	(n, γ): 1951, 1960, 6111 keV			Y
K	(n,n' γ): 2814 keV		Y	Y
Ca	(n,n' γ): 1940 keV (n, γ): 3736 keV	Y	Y	
Fe	(n,n' γ): 846, 1238, 1408, 1809 keV (n, γ): 7631, 7646, keV	Y	Y	
Ni	(n,n' γ): 1332, 1454 keV	Y		





Taken from WANDA 2021 presentation by D. Lawrence and P. Peplowski




ND needs in planetary gamma spectroscopy

Information content

Specific elements via gamma-ray spectroscopy (with help from neutrons)




Lunar elemental maps



ENDF/B-VI - Mg library spectrum required correction

- 1368.6 keV gamma-ray primarily from ²⁴Mg(n,n' γ) represented as a broad peak



Peak analyses - Lawrence et al. (2000, 2002); Spectral unmixing - Prettyman et al. (2006)

LP-GRS artwork: S. Storms, LANL document LA-UR 10-05410

Taken from WANDA 2021 presentation by T. Prettyman



ND needs in planetary gamma spectroscopy

NA-22 has needs for improved benchmark data on a variety of elements that comprise structural and shielding materials, controlled or dangerous substances, and detector materials

- Active neutron interrogation techniques are employed in a variety of nonproliferation applications
- Modeling of secondary γ -ray emission from active neutron interrogation would benefit greatly from quality assurance checks with benchmark datasets
- Improved γ -production cross sections are needed on priority elements
- Benchmark data are primarily required from radiative capture (n,γ) and inelastic scattering ($n,n'\gamma$), depending on which cross sections dominate γ -ray production


First Priority	Follow-up	Remaining	
H	He	F	Gd
C	Li	Mg	Bi
N	Be	P	Np
O	B	S	Am
Na	Cl	Ar	
Al	Cr	K	
Si	Mn	Ca	
Fe	Ni	Ti	
Cu	Ge	As	
Pb	Br	Kr	
W	Cd	Mo	
U	I	Sn	
Pu	Cs	Sb	
	La	Xe	

6

Taken from WANDA 2021 presentation by D. Matters



Problems identified in inelastic/capture gammas of many ENDF/B-VIII.0 evaluations




$\text{Si}(n,n'\gamma)$

Hint:
ENDF/B-VI.8
was better for gammas

Marie-Laure Mauborgne et al, CSWEG 2019 & EPJ WoC **239** (2020) 20007 (ND2019)



Problems identified in inelastic/capture gammas of many ENDF/B-VIII.0 evaluations



$^{56}\text{Fe}(n,\gamma)$

Hint:
ENDF/B-VI.8
was better for gammas

Marie-Laure Mauborgne et al, CSWEG 2019 & EPJ WoC **239** (2020) 20007 (ND2019)



Problems identified in inelastic/capture gammas of many ENDF/B-VIII.0 evaluations




Fig. 9: Comparison of capture γ -ray spectra from the manganese mix from experiment and modeled with various libraries

Similar problems:
 $Mn(n,\gamma)$, $(Si(n,n'\gamma))$,
 $Fe(n,\gamma)$, $Fe(n,n'\gamma)$,
 $Mg(n,\gamma)$, $Mg(n,n'\gamma)$,
 $Ti(n,\gamma)$, $Ti(n,n'\gamma)$


Hint:
ENDF/B-VI.8
was better for gammas

Marie-Laure Mauborgne et al, CSWEG 2019 & EPJ WoC **239** (2020) 20007 (ND2019)


Problems discussed, but not solved

GAMMA PRODUCTION LINES

With the help of IAEA/EGAF measured values, MF6 for gamma production lines for $^{56}\text{Fe}+n_{\text{th}}$ ($\geq\text{JEFF-3.2}$)




^{55}Mn update of thermal (n, γ) gammas



^{55}Mn update of thermal (n, γ) gammas

Thermal capture photon spectrum updated



EGAF IAEA database:
Measured thermal capture γ

Quite challenging to
reproduce via modelling



But very well measured ☺,
Let's use it.

See description in [INDC\(NDS\)-0810](#), performance restored

^{55}Mn update of thermal (n,g) gammas

- ❑ Mn-55 evaluation in ENDF/B-VIII.0 was criticized for poor prediction of capture and inelastic gamma spectra (Marie-Laure Mauborgne, CSEWG-2019, EPJ WoC **239**, 20007 (2020).
- ❑ The data are important for oil-well exploration.
- ❑ Using the information in the EGAF library and EMPIRE nuclear model calculations the gamma production data were improved. High resolution energy bins (~ 5 keV/bin)
- ❑ Good performance of updated file [mn55e80p](#) on proprietary benchmark was confirmed by Marie-Laure Mauborgne (file [mn55e80p](#) available at https://nds.iaea.org/INDEN/data/mn55e80p_ENDF.zip)
- ❑ Documented in [INDC\(NDS\)-0810](#) on "Evaluation of thermal capture gamma spectra"
- ❑ Updated methodology tested to be applied to other evaluations, but:
PUBLIC EXPERIMENTAL BENCHMARKS NEEDED



Summary

- ❑ A non-comprehensive (and biased) selection of nuclear data priorities have been presented as a motivation for nuclear data research
- ❑ Applications like radionuclide production of medical radioisotopes, planetary exploration, space nuclear propulsion, planetary defense, and geological applications have been discussed to highlight associated nuclear data needs
- ❑ Workshop for Applied Nuclear Data Activities (WANDA 2021) is an excellent resource of information: <https://conferences.lbl.gov/event/504/>

